gene_symbol
FCGR3A
hgnc_id
HGNC:3619
binding_type
receptor ligand recognition
cytotoxicity
NO
cytotoxicity_type
INDIRECT
cytotoxicity_mechanism
Dinutuximab binds GD2 on tumor cells; its Fc engages CD16a (FcγRIIIa) on NK cells/macrophages to mediate ADCC/ADCP and complement lysis of GD2+ cells. CD16a-expressing cells act as effectors, not targets, and are not killed.
enzyme_product
Off
epitope
Off
variant
Off
isoform
Off
hla_specific
Off
gated
Off
other_modifier
NK-cell Fc receptor mediating ADCC via IgG1 Fc
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT06450041
disease_id_num_tar_ref
1626
drug_id_num_tar_ref
4400